249 related articles for article (PubMed ID: 37776119)
1. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
2. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
3. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
4. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
[No Abstract] [Full Text] [Related]
5. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
[TBL] [Abstract][Full Text] [Related]
6. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
[No Abstract] [Full Text] [Related]
7. Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine.
Lipton RB; Lee L; Saikali NP; Bell J; Cohen JM
J Manag Care Spec Pharm; 2020 Oct; 26(10):1344-1352. PubMed ID: 32678720
[TBL] [Abstract][Full Text] [Related]
8. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
[TBL] [Abstract][Full Text] [Related]
9. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
[TBL] [Abstract][Full Text] [Related]
10. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
11. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
12. Ketamine: stimulating antidepressant treatment?
Malhi GS; Byrow Y; Cassidy F; Cipriani A; Demyttenaere K; Frye MA; Gitlin M; Kennedy SH; Ketter TA; Lam RW; McShane R; Mitchell AJ; Ostacher MJ; Rizvi SJ; Thase ME; Tohen M
BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
[TBL] [Abstract][Full Text] [Related]
13. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
[TBL] [Abstract][Full Text] [Related]
16. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
[No Abstract] [Full Text] [Related]
17. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
[No Abstract] [Full Text] [Related]
18. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
19. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
[TBL] [Abstract][Full Text] [Related]
20. Place of care and costs associated with acute episodes and remission in schizophrenia.
McIntyre RS; Higa S; Doan QV; Amari DT; Mercer D; Gillard P; Harrington A
J Manag Care Spec Pharm; 2023 May; 29(5):499-508. PubMed ID: 37121252
[No Abstract] [Full Text] [Related]
[Next] [New Search]
